Post-treatment alpha-fetoprotein response predicts prognosis of patients with hepatocellular carcinoma: A meta-analysis

Medicine (Baltimore). 2019 Aug;98(31):e16557. doi: 10.1097/MD.0000000000016557.

Abstract

Background: Post-treatment alpha-fetoprotein (AFP) response has been reported to be associated with prognosis of hepatocellular carcinoma (HCC) patients, but the results were not consistent. This meta-analysis aimed to explore the relationship between AFP response and clinical outcomes of HCC.

Methods: PubMed, Embase, Medline and Cochrane library were searched for relevant articles published before March 20, 2019. The data were analyzed using RevMan5.3 software.

Results: Twenty-nine articles with 4726 HCC patients were finally included for analysis. The pooled results showed that post-treatment AFP response was significantly associated with overall survival (OS) (hazard ratio (HR) = 0.41, 95% confidence interval (CI): 0.35-0.47, P <.001), progression free survival (PFS) (HR = 0.46, 95% CI: 0.39-0.54, P <.001) and recurrence free survival (RFS) (HR = 0.41, 95% CI: 0.29-0.56, P <.001) of HCC patients.

Conclusion: post-treatment AFP response might be a useful prognostic marker for HCC patients.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Humans
  • Liver Neoplasms / drug therapy*
  • Prognosis*
  • alpha-Fetoproteins / metabolism*
  • alpha-Fetoproteins / therapeutic use

Substances

  • alpha-Fetoproteins